

IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. (canceled)

2. (canceled)

3. (canceled)

4. (canceled)


5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (currently amended) A method for the treatment of malaria which comprises administering to a patient in need of such treatment a compound of formula I:



wherein,

R⁵ is hydrogen;

~~R⁵, R^{1a} and R¹ independently are hydrogen, C₁₋₆ alkyl, tert-butyl, halo, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, or and trihalovinyl, wherein said aryl is optionally substituted with 1-3 groups of R^a;~~

each R² is hydrogen, C₁₋₆ alkyl, ~~or and~~ C₃₋₁₀ cycloalkyl; or alternatively both R² groups are taken together with any intervening atoms ~~to can~~ form a ~~3 to 7 membered carbocyclic or~~ heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

R^{2a} is hydrogen, ~~and~~ or C₁₋₆ alkyl;

R³ and R^{3a} are independently hydrogen, halo, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, ~~or and~~ C₆₋₁₀ aryl, wherein said aryl and alkyl are each optionally substituted with 1-3 groups of R^a; or

R³ and R^{3a} are taken together with any intervening atoms ~~to can~~ form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO₂, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;

R⁴ is hydrogen, halo, C₁₋₆ alkyl, ~~or and~~ trihaloalkyl;

R^a represents C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen; and

n represents 1-3;

or a pharmaceutically acceptable salt, enantiomer, or diastereomer ~~diastereomer~~ thereof.

10. (currently amended) A method according to claim 9 wherein the compound is selected from the group consisting of:

2-aminomethyl-5-tert-butyl-3-phenylphenol,
2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,
3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,

2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,
tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,
3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(allylamino)methyl]phenol,
5-tert-butyl-2-[(ethylamino)methyl]phenol,
2-[(benzylamino)methyl]-5-tert-butylphenol,
5-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
2-[(cyclohexylamino)methyl]-5-(trichlorovinyl)phenol,
5-tert-butyl-2-[(2-phenylethyl)amino]methyl]phenol,
2-[(benzylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(decylamino)methyl]phenol,
2-[(propylamino)methyl]-5-(trichlorovinyl)phenol,
5-tert-butyl-2-[(propylamino)methyl]phenol,
5-tert-butyl-2-[(cyclopropylamino)methyl]phenol,
5-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]phenol,
2-[(cyclopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(isopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[[[(1R)-1-phenylethyl]amino]methyl]phenol,
3,5-di-tert-butyl-2-[[[(1-naphthyl)methyl]amino]methyl]phenol,
3,5-di-tert-butyl-2-[[[(2-naphthyl)methyl]amino]methyl]phenol,
2-[(tert-butylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-2-ylamino)methyl]phenol,
2-[(cyclohexylamino)methyl]-3-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
3,5-di-tert-butyl-2-[[[(1R)-2,3-dihydro-1H-inden-1-ylamino]methyl]phenol,
3,5-di-tert-butyl-2-[[[(1S)-2,3-dihydro-1H-inden-1-ylamino]methyl]phenol,

~~5-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,~~
~~5-tert-butyl-2-[[[(4-methoxybenzyl)amino]methyl]phenol,~~
~~5-tert-butyl-2-[(neopentylamino)methyl]phenol,~~
~~5-tert-butyl-2-[[[(3,3-dimethylbutyl)amino]methyl]phenol,~~
~~5-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,~~
~~5-tert-butyl-2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]phenol,~~
~~5-tert-butyl-2-[(isopropylamino)methyl]phenol,~~
~~3,5-di-tert-butyl-2-[(decahydronaphthalen-2-ylamino)methyl]phenol,~~
~~5-tert-butyl-2-[(isopentylamino)methyl]phenol,~~
~~5-tert-butyl-2-[(isobutylamino)methyl]phenol,~~
~~5-tert-butyl-2-(piperidin-1-ylmethyl)phenol,~~
~~3,5-di-tert-butyl-2-[[[(2-pyridin-2-ylethyl)amino]methyl]phenol,~~
~~3,5-di-tert-butyl-2-[[[(2-pyridin-3-ylethyl)amino]methyl]phenol,~~
~~3,5-di-tert-butyl-2-[[[(2-pyridin-4-ylethyl)amino]methyl]phenol,~~
~~3,5-di-tert-butyl-2-[(tetrahydro-2H-pyran-4-ylamino)methyl]phenol,~~
~~3,5-di-tert-butyl-2-[[[(cyclohexylmethyl)amino]methyl]phenol,~~
~~2-(aminomethyl)-3,5-di-tert-butylphenol,~~
~~5-tert-butyl-2-[[[(3-methoxybenzyl)amino]methyl]phenol,~~
~~2-(aminomethyl)-4-bromo-5-tert-butylphenol,~~
~~ethyl N-(2,4-ditert-butyl-6-hydroxybenzyl)-beta-alaninate,~~
~~3-tert-butyl-2-(piperidin-1-ylmethyl)phenol,~~
~~3-tert-butyl-2-[(cyclohexylamino)methyl]phenol,~~
~~2-[2-(cyclohexylamino)ethyl]-5-(trichlorovinyl)phenol,~~
~~3-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,~~
~~3,5-di-tert-butyl-2-[[[(tetrahydro-2H-pyran-2-ylmethyl)amino]methyl]phenol,~~
~~3,5-di-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,~~
~~3,5-di-tert-butyl-2-[[[(3-furylmethyl)amino]methyl]phenol,~~
~~2-[2-(benzylamino)ethyl]-3,5-ditert-butylphenol,~~
~~2-(Aminomethyl)-3-tert-butyl-5-methylphenol,~~
~~3-(Aminomethyl)-4,6-di-tert-butyl-4'-chlorobiphenyl-2-ol,~~
~~4,6-Di-tert-butyl-3-[(tert-butylamino)methyl]-4'-chlorobiphenyl-2-ol,~~
~~4,6-di-Tert-butyl-3-[(butylamino)methyl]-4'-chlorobiphenyl-2-ol,~~
~~4,6-Di-tert-butyl-4'-chloro-3-[(dimethylamino)methyl]biphenyl-2-ol,~~
~~4,6-Di-tert-butyl-4'-chloro-3-[(diethylamino)methyl]biphenyl-2-ol,~~
~~5-Tert-butyl-2-[2-(dimethylamino)ethyl]phenol,~~

~~5-*Tert*-butyl-2-[2-(methylamino)ethyl]phenol,~~
~~2-(2-aminoAminoethyl)-3,5-di-*tert*-butylphenol,~~
~~2-(Aminomethyl)-5-*tert*-butyl-3-methylphenol,~~
~~2-(aminoAminomethyl)-3,5-bis(trichlorovinyl)phenol,~~
~~2-(Aminomethyl)-5-(trichlorovinyl)phenol,~~
~~3,5-Di-*tert*-butyl-2-[[[(1,4-dioxan-2-ylmethyl)amino]methyl]phenol,~~
~~3,5-di-*tert*-butyl-2-[[[(1,1-dioxido-tetrahydro-3-thienyl)methyl]amino]methyl]phenol,~~
~~5-[[[(2,4-di-*tert*-butyl-6-hydroxybenzyl)amino]methyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one,~~
~~2-(1-aminoAminoethyl)-3,5-di-*tert*-butylphenol,~~
~~3,5-di-Di-*tert*-butyl-2-[1-(ethylamino)ethyl]phenol,~~
~~3,5-di-Di-*tert*-butyl-2-[(propylamino)methyl]phenol,~~
~~3,5-Di-*tert*-butyl-2-[[[(pyrazin-2-ylmethyl)amino]methyl]phenol,~~
~~2-(aminomethyl)-3,5-di-*tert*-butylphenol hydrochloride,~~
~~2-Aminomethyl-5-*tert*-butylphenol hydrochloride,~~
and pharmaceutically acceptable salts thereof.

11. (original) A method according to claim 9 wherein a second anti-malarial agent is administered said second anti-malarial agent selected from the group consisting of Chloroquine, Fansidar, Amodiaquine, Quinine, Halofantrine, Mefloquine, Artemether/Artesunate and Malarone.

12. (currently amended) A method according to claim 9, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, R^{1a} and R¹ independently are ~~hydrogen~~, *tert*-butyl, 1,2,2-trichlorovinyl, or phenyl.

13. (previously presented) A method according to claim 9, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, R² is hydrogen or C₁₋₄ alkyl; and n is 1.

14. (currently amended) A method according to claim 9, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, R^{1a} and R¹ independently are ~~hydrogen~~, *tert*-butyl, 1,2,2-trichlorovinyl, or phenyl; R² is hydrogen or C₁₋₄ alkyl; and n is 1.

15. (previously presented) A method according to claim 14, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, R^{1a} and R¹ are tert-butyl; and R² is hydrogen.

16. (previously presented) A method according to claim 15, wherein the compound of formula I is 2-(aminomethyl)-3,5-di-tert-butylphenol or a pharmaceutically acceptable salt thereof.

17. (new) A method according to claim 16, wherein the compound of formula I is 2-(aminomethyl)-3,5-di-tert-butylphenol hydrochloride.

18. (new) A method according to claim 16, wherein a second anti-malarial agent is administered said second anti-malarial agent selected from the group consisting of Chloroquine, Fansidar, Amodiaquine, Quinine, Halofantrine, Mefloquine, Artemether/Artesunate and Malarone.

19. (new) A method according to claim 16, wherein the compound or its pharmaceutically acceptable salt is a component in a pharmaceutical composition that also comprises a pharmaceutically acceptable carrier.

20. (new) A method according to claim 9, wherein the compound of formula I or its pharmaceutically acceptable salt is a component in a pharmaceutical composition that also comprises a pharmaceutically acceptable carrier.

21. (new) A compound selected from the group consisting of:
2-aminomethyl-5-tert-butyl-3-phenylphenol,
2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,
3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,

3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,
tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,
3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(allylamino)methyl]phenol,
5-tert-butyl-2-[(ethylamino)methyl]phenol,
2-[(benzylamino)methyl]-5-tert-butylphenol,
2-[(cyclohexylamino)methyl]-5-(trichlorovinyl)phenol,
5-tert-butyl-2-{[(2-phenylethyl)amino]methyl}phenol,
2-[(benzylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(decylamino)methyl]phenol,
2-[(propylamino)methyl]-5-(trichlorovinyl)phenol,
5-tert-butyl-2-[(propylamino)methyl]phenol,
5-tert-butyl-2-[(cyclopropylamino)methyl]phenol,
5-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]phenol,
2-[(cyclopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(isopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-{[(1R)-1-phenylethyl]amino}methyl}phenol,
3,5-di-tert-butyl-2-{[(1-naphthylmethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2-{[(2-naphthylmethyl)amino]methyl}phenol,
2-[(tert-butylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-2-ylamino)methyl]phenol,
2-[(cyclohexylamino)methyl]-3-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
3,5-di-tert-butyl-2-{[(1R)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol,
3,5-di-tert-butyl-2-{[(1S)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol,
5-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
5-tert-butyl-2-{[(4-methoxybenzyl)amino]methyl}phenol,
5-tert-butyl-2-[(neopentylamino)methyl]phenol,
5-tert-butyl-2-{[(3,3-dimethylbutyl)amino]methyl}phenol,

5-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
5-tert-butyl-2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(decahydronaphthalen-2-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopentylamino)methyl]phenol,
5-tert-butyl-2-[(isobutylamino)methyl]phenol,
5-tert-butyl-2-(piperidin-1-ylmethyl)phenol,
3,5-di-tert-butyl-2-{[(2-pyridin-2-ylethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2-{[(2-pyridin-3-ylethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2-{[(2-pyridin-4-ylethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2-[(tetrahydro-2H-pyran-4-ylamino)methyl]phenol,
3,5-di-tert-butyl-2-{[(cyclohexylmethyl)amino]methyl}phenol,
5-tert-butyl-2-{[(3-methoxybenzyl)amino]methyl}phenol,
2-(aminomethyl)-4-bromo-5-tert-butylphenol,
ethyl N-(2,4-ditert-butyl-6-hydroxybenzyl)-beta-alaninate,
3-tert-butyl-2-(piperidin-1-ylmethyl)phenol,
3-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
2-[2-(cyclohexylamino)ethyl]-5-(trichlorovinyl)phenol,
3-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
3,5-di-tert-butyl-2-{[(tetrahydro-2H-pyran-2-ylmethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
3,5-di-tert-butyl-2-{[(3-furylmethyl)amino]methyl}phenol,
2-[2-(benzylamino)ethyl]-3,5-ditert-butylphenol,
2-(aminomethyl)-3-tert-butyl-5-methylphenol,
3-(aminomethyl)-4,6-di-tert-butyl-4'-chlorobiphenyl-2-ol,
4,6-di-tert-butyl-3-[(tert-butylamino)methyl]-4'-chlorobiphenyl-2-ol,
4,6-di-tert-butyl-3-[(butylamino)methyl]-4'-chlorobiphenyl-2-ol,
4,6-di-tert-butyl-4'-chloro-3-[(dimethylamino)methyl]biphenyl-2-ol,
4,6-di-tert-butyl-4'-chloro-3-[(diethylamino)methyl]biphenyl-2-ol,
5-tert-butyl-2-[2-(dimethylamino)ethyl]phenol,
5-tert-butyl-2-[2-(methylamino)ethyl]phenol,
2-(2-aminoethyl)-3,5-di-tert-butylphenol,
2-(aminomethyl)-5-tert-butyl-3-methylphenol,
2-(aminomethyl)-3,5-bis(trichlorovinyl)phenol,
2-(aminomethyl)-5-(trichlorovinyl)phenol,

3,5-di-tert-butyl-2-([(1,4-dioxan-2-ylmethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2-([(1,1-dioxidotetrahydro-3-thienyl)methyl]amino}methyl)phenol,
5-([(2,4-di-tert-butyl-6-hydroxybenzyl)amino]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one,
2-(1-aminoethyl)-3,5-di-tert-butylphenol,
3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(pyrazin-2-ylmethyl)amino]methyl}phenol,
2-aminomethyl-5-tert-butylphenol,
and pharmaceutically acceptable salts thereof.

22. (new) A composition comprising a compound of claim 21 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

23. (new) A method for the treatment of malaria which comprises administering to a patient in need of such treatment a compound selected from the group consisting of:

2-aminomethyl-5-tert-butyl-3-phenylphenol,
2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,
3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
2-[(ethylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(octylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-hydroxyethylamino)methyl]phenol,
tert-butyl N-(2,4-di-tert-butyl-6-hydroxybenzyl)-beta-alaninate,
3,5-di-tert-butyl-2-[(2-dimethylaminoethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(3-phenylpropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(2-phenylethylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(allylamino)methyl]phenol,
5-tert-butyl-2-[(ethylamino)methyl]phenol,

2-[(benzylamino)methyl]-5-tert-butylphenol,
2-[(cyclohexylamino)methyl]-5-(trichlorovinyl)phenol,
5-tert-butyl-2- {[(2-phenylethyl)amino]methyl}phenol,
2-[(benzylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(decylamino)methyl]phenol,
2-[(propylamino)methyl]-5-(trichlorovinyl)phenol,
5-tert-butyl-2-[(propylamino)methyl]phenol,
5-tert-butyl-2-[(cyclopropylamino)methyl]phenol,
5-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]phenol,
2-[(cyclopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(isopropylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(1,2,3,4-tetrahydronaphthalen-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2- {[(1R)-1-phenylethyl]amino}methyl}phenol,
3,5-di-tert-butyl-2- {[(1-naphthylmethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2- {[(2-naphthylmethyl)amino]methyl}phenol,
2-[(tert-butylamino)methyl]-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(1,2,3,4-tetrahydronaphthalen-2-ylamino)methyl]phenol,
2-[(cyclohexylamino)methyl]-3-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
3,5-di-tert-butyl-2- {[(1R)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol,
3,5-di-tert-butyl-2- {[(1S)-2,3-dihydro-1H-inden-1-ylamino]methyl}phenol,
5-tert-butyl-2-[(2,3-dihydro-1H-inden-2-ylamino)methyl]phenol,
5-tert-butyl-2- {[(4-methoxybenzyl)amino]methyl}phenol,
5-tert-butyl-2-[(neopentylamino)methyl]phenol,
5-tert-butyl-2- {[(3,3-dimethylbutyl)amino]methyl}phenol,
5-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
5-tert-butyl-2-[(2,3-dihydro-1H-inden-1-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopropylamino)methyl]phenol,
3,5-di-tert-butyl-2-[(decahydronaphthalen-2-ylamino)methyl]phenol,
5-tert-butyl-2-[(isopentylamino)methyl]phenol,
5-tert-butyl-2-[(isobutylamino)methyl]phenol,
5-tert-butyl-2-(piperidin-1-ylmethyl)phenol,
3,5-di-tert-butyl-2- {[(2-pyridin-2-ylethyl)amino]methyl}phenol,
3,5-di-tert-butyl-2- {[(2-pyridin-3-ylethyl)amino]methyl}phenol,

3,5-di-tert-butyl-2-[[(2-pyridin-4-ylethyl)amino]methyl]phenol,
3,5-di-tert-butyl-2-[(tetrahydro-2H-pyran-4-ylamino)methyl]phenol,
3,5-di-tert-butyl-2-[[(cyclohexylmethyl)amino]methyl]phenol,
5-tert-butyl-2-[[(3-methoxybenzyl)amino]methyl]phenol,
2-(aminomethyl)-4-bromo-5-tert-butylphenol,
ethyl N-(2,4-ditert-butyl-6-hydroxybenzyl)-beta-alaninate,
3-tert-butyl-2-(piperidin-1-ylmethyl)phenol,
3-tert-butyl-2-[(cyclohexylamino)methyl]phenol,
2-[2-(cyclohexylamino)ethyl]-5-(trichlorovinyl)phenol,
3-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[[(tetrahydro-2H-pyran-2-ylmethyl)amino]methyl]phenol,
3,5-di-tert-butyl-2-[2-(cyclohexylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[[(3-furylmethyl)amino]methyl]phenol,
2-[2-(benzylamino)ethyl]-3,5-ditert-butylphenol,
2-(aminomethyl)-3-tert-butyl-5-methylphenol,
3-(aminomethyl)-4,6-di-tert-butyl-4'-chlorobiphenyl-2-ol,
4,6-di-tert-butyl-3-[(tert-butylamino)methyl]-4'-chlorobiphenyl-2-ol,
4,6-di-tert-butyl-3-[(butylamino)methyl]-4'-chlorobiphenyl-2-ol,
4,6-di-tert-butyl-4'-chloro-3-[(dimethylamino)methyl]biphenyl-2-ol,
4,6-di-tert-butyl-4'-chloro-3-[(diethylamino)methyl]biphenyl-2-ol,
5-tert-butyl-2-[2-(dimethylamino)ethyl]phenol,
5-tert-butyl-2-[2-(methylamino)ethyl]phenol,
2-(2-aminoethyl)-3,5-di-tert-butylphenol,
2-(aminomethyl)-5-tert-butyl-3-methylphenol,
2-(aminomethyl)-3,5-bis(trichlorovinyl)phenol,
2-(aminomethyl)-5-(trichlorovinyl)phenol,
3,5-di-tert-butyl-2-[[(1,4-dioxan-2-ylmethyl)amino]methyl]phenol,
3,5-di-tert-butyl-2-([[(1,1-dioxidotetrahydro-3-thienyl)methyl]amino}methyl]phenol,
5-[[(2,4-di-tert-butyl-6-hydroxybenzyl)amino]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one,
2-(1-aminoethyl)-3,5-di-tert-butylphenol,
3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,
3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,
3,5-di-tert-butyl-2-[[(pyrazin-2-ylmethyl)amino]methyl]phenol,
2-(aminomethyl)-3,5-di-tert-butylphenol,
2-aminomethyl-5-tert-butylphenol,

and pharmaceutically acceptable salts thereof.

24. (new) A method according to claim 23, wherein the compound or its pharmaceutically acceptable salt is a component in a pharmaceutical composition that also comprises a pharmaceutically acceptable carrier.

25. (new) A method according to claim 23, wherein a second anti-malarial agent is administered wherein said second anti-malarial agent selected from the group consisting of Chloroquine, Fansidar, Amodiaquine, Quinine, Halofantrine, Mefloquine, Artemether/Artesunate and Malarone.